Human extracellular matrix (ECM) drug target discovery platform.
Engitix has raised €69M across 2 funding rounds from 3 investors, most recently a Series A round in Jan 2026. Based in London, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2026-01-08 | Series A | €21M | Mike Platt,Netherton Investments | View deal → |
| 2022-01-19 | Series A | €48M | Dompé,Netherton Investments | View deal → |
